All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cancer location (gastric) cancer location (gastro-esophageal) ECOG 0 ECOG 1 Gender, female Gender, male metastasis (liver ) PD-L1 < 1% PD-L1 > 1% previous gastrectomy previous gastrectomy NO
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mGC or mGEJC - L2 - all population, immune chekpoint inhibitors vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ATTRACTION-2 (Kang), 2017 0.63 [0.51; 0.78]
CA184-162, 2017 1.54 [0.73; 3.26]
JAVELIN Gastric 300, 2018 1.10 [0.88; 1.37]
KEYNOTE-061 (all population), 2018 0.94 [0.79; 1.12]
0.92 [0.69 ; 1.24 ] ATTRACTION-2 (Kang), 2017, CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 4 81% 1,570 moderate not evaluable deaths (OS) (extension)detailed results ATTRACTION-2 (Kang), 2017 0.62 [0.51; 0.76]
0.62 [0.51 ; 0.76 ] ATTRACTION-2 (Kang), 2017 1 0% 493 NA not evaluable PFS (extension)detailed results ATTRACTION-2 (Kang), 2017 0.60 [0.48; 0.74]
0.60 [0.48 ; 0.74 ] ATTRACTION-2 (Kang), 2017 1 0% 493 NA not evaluable progression or deaths (PFS)detailed results ATTRACTION-2 (Kang), 2017 0.60 [0.48; 0.74]
CA184-162, 2017 1.59 [1.20; 2.10]
JAVELIN Gastric 300, 2018 1.73 [1.38; 2.17]
KEYNOTE-061 (all population), 2018 1.49 [1.25; 1.77]
1.25 [0.77 ; 2.04 ] ATTRACTION-2 (Kang), 2017, CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 4 95% 1,570 moderate not evaluable DCRdetailed results ATTRACTION-2 (Kang), 2017 1.99 [1.24; 3.18]
JAVELIN Gastric 300, 2018 0.37 [0.23; 0.60]
0.86 [0.17 ; 4.45 ] ATTRACTION-2 (Kang), 2017, JAVELIN Gastric 300, 2018 2 96% 864 low not evaluable irORRdetailed results CA184-162, 2017 0.24 [0.03; 2.19]
0.24 [0.03 ; 2.19 ] CA184-162, 2017 1 0% 114 NA not evaluable irPFSdetailed results CA184-162, 2017 1.44 [1.09; 1.91]
1.44 [1.09 ; 1.91 ] CA184-162, 2017 1 0% 114 NA not evaluable objective responses (ORR)detailed results ATTRACTION-2 (Kang), 2017 34.90 [2.12; 573.88]
JAVELIN Gastric 300, 2018 0.49 [0.15; 1.66]
KEYNOTE-061 (all population), 2018 0.88 [0.53; 1.45]
1.32 [0.32 ; 5.44 ] ATTRACTION-2 (Kang), 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 3 73% 1,456 moderate not evaluable AE (any grade)detailed results ATTRACTION-2 (Kang), 2017 1.93 [1.10; 3.38]
1.93 [1.10 ; 3.38 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.10 [0.75; 1.62]
1.10 [0.75 ; 1.62 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable AE leading to death (grade 5)detailed results ATTRACTION-2 (Kang), 2017 0.65 [0.37; 1.12]
0.65 [0.37 ; 1.12 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results ATTRACTION-2 (Kang), 2017 0.93 [0.45; 1.92]
0.93 [0.45 ; 1.92 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.69 [0.29; 1.66]
0.69 [0.29 ; 1.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable SAE (any grade)detailed results ATTRACTION-2 (Kang), 2017 0.75 [0.52; 1.10]
0.75 [0.52 ; 1.10 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable SAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.92 [0.61; 1.40]
0.92 [0.61 ; 1.40 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable STRAE (any grade)detailed results ATTRACTION-2 (Kang), 2017 2.13 [0.96; 4.71]
2.13 [0.96 ; 4.71 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable STRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 2.67 [0.90; 7.91]
2.67 [0.90 ; 7.91 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable TRAE (any grade)detailed results ATTRACTION-2 (Kang), 2017 2.05 [1.36; 3.09]
CA184-162, 2017 2.05 [0.90; 4.67]
JAVELIN Gastric 300, 2018 0.34 [0.22; 0.52]
KEYNOTE-061 (all population), 2018 0.21 [0.14; 0.31]
0.72 [0.22 ; 2.40 ] ATTRACTION-2 (Kang), 2017, CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 4 96% 1,524 moderate not evaluable TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 2.53 [1.09; 5.83]
CA184-162, 2017 3.03 [0.91; 10.04]
JAVELIN Gastric 300, 2018 0.22 [0.12; 0.40]
KEYNOTE-061 (all population), 2018 0.31 [0.21; 0.47]
0.78 [0.25 ; 2.48 ] ATTRACTION-2 (Kang), 2017, CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 4 91% 1,524 moderate not evaluable TRAE leading to death (grade 5)detailed results ATTRACTION-2 (Kang), 2017 1.22 [0.23; 6.37]
CA184-162, 2017 1.92 [0.55; 6.70]
JAVELIN Gastric 300, 2018 0.48 [0.02; 14.39]
KEYNOTE-061 (all population), 2018 2.84 [0.29; 27.42]
1.63 [0.68 ; 3.94 ] ATTRACTION-2 (Kang), 2017, CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 4 0% 1,524 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results ATTRACTION-2 (Kang), 2017 1.10 [0.33; 3.63]
CA184-162, 2017 1.00 [0.02; 51.28]
JAVELIN Gastric 300, 2018 0.74 [0.27; 2.03]
KEYNOTE-061 (all population), 2018 0.55 [0.24; 1.28]
0.71 [0.41 ; 1.25 ] ATTRACTION-2 (Kang), 2017, CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 4 0% 1,536 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.65 [0.14; 2.92]
0.65 [0.14 ; 2.92 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Alopecia TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 0.96 [0.02; 48.74]
KEYNOTE-061 (all population), 2018 0.16 [0.01; 3.11]
0.30 [0.03 ; 3.29 ] JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 2 0% 931 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 0.04 [0.00; 0.71]
KEYNOTE-061 (all population), 2018 0.54 [0.21; 1.38]
0.21 [0.02 ; 2.39 ] JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 2 65% 931 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results CA184-162, 2017 1.59 [0.05; 48.47]
JAVELIN Gastric 300, 2018 0.19 [0.02; 1.63]
0.36 [0.05 ; 2.42 ] CA184-162, 2017, JAVELIN Gastric 300, 2018 2 7% 463 moderate not evaluable Colitis TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
CA184-162, 2017 4.94 [0.24; 101.33]
KEYNOTE-061 (all population), 2018 0.16 [0.01; 3.11]
0.90 [0.12 ; 6.89 ] ATTRACTION-2 (Kang), 2017, CA184-162, 2017, KEYNOTE-061 (all population), 2018 3 21% 1,163 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.22; 17.71]
CA184-162, 2017 1.59 [0.05; 48.47]
JAVELIN Gastric 300, 2018 0.12 [0.01; 2.25]
KEYNOTE-061 (all population), 2018 3.77 [0.17; 84.06]
1.14 [0.27 ; 4.78 ] ATTRACTION-2 (Kang), 2017, CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 4 4% 1,524 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.94 [0.02; 47.47]
0.94 [0.02 ; 47.47 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.09; 43.66]
CA184-162, 2017 8.56 [0.45; 161.00]
JAVELIN Gastric 300, 2018 0.16 [0.02; 1.31]
KEYNOTE-061 (all population), 2018 0.94 [0.06; 15.08]
1.01 [0.17 ; 5.89 ] ATTRACTION-2 (Kang), 2017, CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 4 41% 1,524 moderate not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CA184-162, 2017 0.79 [0.02; 40.48]
0.79 [0.02 ; 40.48 ] CA184-162, 2017 1 0% 102 NA not evaluable Fatigue TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.48 [0.07; 3.47]
CA184-162, 2017 3.24 [0.14; 73.60]
JAVELIN Gastric 300, 2018 0.48 [0.04; 5.32]
KEYNOTE-061 (all population), 2018 0.49 [0.19; 1.26]
0.55 [0.25 ; 1.19 ] ATTRACTION-2 (Kang), 2017, CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 4 0% 1,524 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 0.08 [0.00; 1.40]
0.08 [0.00 ; 1.40 ] JAVELIN Gastric 300, 2018 1 0% 361 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 7.60 [0.40; 144.43]
7.60 [0.40 ; 144.43 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
KEYNOTE-061 (all population), 2018 0.94 [0.02; 47.47]
0.68 [0.04 ; 10.84 ] ATTRACTION-2 (Kang), 2017, KEYNOTE-061 (all population), 2018 2 0% 1,061 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 3.77 [0.17; 84.06]
3.77 [0.17 ; 84.06 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
CA184-162, 2017 3.24 [0.14; 73.60]
KEYNOTE-061 (all population), 2018 23.34 [3.13; 174.05]
5.44 [0.62 ; 47.88 ] ATTRACTION-2 (Kang), 2017, CA184-162, 2017, KEYNOTE-061 (all population), 2018 3 41% 1,163 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.09; 43.66]
JAVELIN Gastric 300, 2018 1.29 [0.28; 5.84]
1.40 [0.36 ; 5.43 ] ATTRACTION-2 (Kang), 2017, JAVELIN Gastric 300, 2018 2 0% 852 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
JAVELIN Gastric 300, 2018 0.72 [0.16; 3.25]
0.75 [0.19 ; 3.00 ] ATTRACTION-2 (Kang), 2017, JAVELIN Gastric 300, 2018 2 0% 852 moderate not evaluable Increased lipase level TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 0.48 [0.04; 5.32]
0.48 [0.04 ; 5.32 ] JAVELIN Gastric 300, 2018 1 0% 361 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 1.93 [0.06; 57.86]
KEYNOTE-061 (all population), 2018 0.47 [0.02; 14.02]
0.95 [0.09 ; 10.52 ] JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 2 0% 931 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Myalgia TRAE (grade 3-4)detailed results CA184-162, 2017 0.79 [0.02; 40.48]
0.79 [0.02 ; 40.48 ] CA184-162, 2017 1 0% 102 NA not evaluable Nausea TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
CA184-162, 2017 0.79 [0.02; 40.48]
JAVELIN Gastric 300, 2018 0.24 [0.01; 5.32]
KEYNOTE-061 (all population), 2018 0.47 [0.04; 5.19]
0.43 [0.09 ; 2.07 ] ATTRACTION-2 (Kang), 2017, CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 4 0% 1,524 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 0.02 [0.00; 0.30]
KEYNOTE-061 (all population), 2018 0.02 [0.00; 0.25]
0.02 [0.00 ; 0.12 ] JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 2 0% 931 moderate not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CA184-162, 2017 0.19 [0.01; 4.33]
0.19 [0.01 ; 4.33 ] CA184-162, 2017 1 0% 102 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.47 [0.02; 14.02]
0.47 [0.02 ; 14.02 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CA184-162, 2017 0.79 [0.02; 40.48]
KEYNOTE-061 (all population), 2018 0.08 [0.00; 1.38]
0.17 [0.02 ; 1.78 ] CA184-162, 2017, KEYNOTE-061 (all population), 2018 2 0% 672 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
KEYNOTE-061 (all population), 2018 3.77 [0.17; 84.06]
2.04 [0.21 ; 20.20 ] ATTRACTION-2 (Kang), 2017, KEYNOTE-061 (all population), 2018 2 0% 1,061 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
CA184-162, 2017 0.79 [0.02; 40.48]
0.62 [0.04 ; 9.98 ] ATTRACTION-2 (Kang), 2017, CA184-162, 2017 2 0% 593 low not evaluable Pyrexia TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Rash TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
CA184-162, 2017 0.79 [0.02; 40.48]
0.62 [0.04 ; 9.98 ] ATTRACTION-2 (Kang), 2017, CA184-162, 2017 2 0% 593 low not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 1.88 [0.06; 56.28]
1.88 [0.06 ; 56.28 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CA184-162, 2017 0.79 [0.02; 40.48]
JAVELIN Gastric 300, 2018 0.24 [0.01; 5.32]
0.38 [0.03 ; 4.32 ] CA184-162, 2017, JAVELIN Gastric 300, 2018 2 0% 463 moderate not evaluable Weight decreased TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 0.07 [0.00; 1.17]
0.07 [0.00 ; 1.17 ] JAVELIN Gastric 300, 2018 1 0% 361 NA not evaluable Abdominal pain AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.14 [0.43; 3.04]
1.14 [0.43 ; 3.04 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Anaemia AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.97 [0.54; 1.75]
0.97 [0.54 ; 1.75 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Asthenia AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 2.48 [0.54; 11.47]
2.48 [0.54 ; 11.47 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Back pain AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.73 [0.12; 4.41]
0.73 [0.12 ; 4.41 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Constipation AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Decreased appetite AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.54 [0.20; 1.42]
0.54 [0.20 ; 1.42 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Diarrhoea AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.22; 17.71]
1.96 [0.22 ; 17.71 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Dyspepsia AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Dyspnoea AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.09; 43.66]
1.96 [0.09 ; 43.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Fatigue AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.29 [0.07; 1.21]
0.29 [0.07 ; 1.21 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Increase AST AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.48 [0.47; 4.67]
1.48 [0.47 ; 4.67 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Increased ALT AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.31 [0.34; 5.00]
1.31 [0.34 ; 5.00 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Nausea AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.24 [0.02; 2.68]
0.24 [0.02 ; 2.68 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Pruritus AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Pyrexia AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.47 [0.15; 14.22]
1.47 [0.15 ; 14.22 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Rash AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Vomiting AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.65 [0.14; 2.92]
0.65 [0.14 ; 2.92 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Weight decreased AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 14:48 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 123
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743